Dimerix acquired a Phase 2-ready clinical asset, DMX-652, which the company says could move quickly into a Phase 2 study under an open US Investigational New Drug (IND) application. The initial focus is acute kidney injury (AKI), targeting a high-need area. Overall, the deal improves the company’s near-term clinical pipeline visibility and progression prospects.
Dimerix acquired a Phase 2-ready clinical asset, DMX-652, which the company says could move quickly into a Phase 2 study under an open US Investigational New Drug (IND) application. The initial focus is acute kidney injury (AKI), targeting a high-need area. Overall, the deal improves the company’s near-term clinical pipeline visibility and progression prospects.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.28
